Literature DB >> 10075158

Measles immunity and vaccination policy in Catalonia.

A Domínguez1, J Vidal, P Plans, G Carmona, P Godoy, J Batalla, L Salleras.   

Abstract

The prevalence of antibodies against measles in a representative sample of the school population in Catalonia was established and the results compared with previous studies. The study was carried out in 1996 using blood samples obtained from schoolchildren aged 6-7 years, 10-11 years, 13 14 years and 15-16 years. 1231 schoolchildren were studied. The global prevalence of antibodies was 96.3%, and a considerable increase was observed with respect to the prevalence in 1986 (89.4%). The level of antibodies was 94% at 6-7 years and 10-11 years, 99.7% at 13-14 years and 98.3% at 15 16 years. These data would suggest the advancement of the administration of the second dose of measles-mumps rubella vaccine to 4 6 years instead of at 11 years.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10075158     DOI: 10.1016/s0264-410x(98)00230-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

2.  Seroprevalence of measles, rubella, and mumps antibodies in Catalonia, Spain: results of a cross-sectional study.

Authors:  A Domínguez; P Plans; J Costa; N Torner; N Cardenosa; J Batalla; A Plasencia; L Salleras
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-05       Impact factor: 3.267

3.  Results of the rubella elimination program in Catalonia (Spain), 2002-2011.

Authors:  Irene Barrabeig; Nuria Torner; Ana Martínez; Gloria Carmona; Pilar Ciruela; Joan Batalla; Josep Costa; Sergi Hernández; Luis Salleras; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-08       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.